市場調查報告書
商品編碼
879105

全球DuloxetineAPI市場預測

Global Duloxetine API Market Research Report Forecast to 2023

出版日期: | 出版商: Market Research Future | 英文 105 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

本報告提供全球DuloxetineAPI市場相關調查分析,提供市場概要,市場趨勢,推動市場的要素/抑制因素等相關考察,各用途,各地區市場分析,主要企業的簡介等相關整體分析。

第1章 摘要整理

第2章 市場簡介

第3章 調查方法

第4章 市場動態

  • 概要
  • 促進要素
  • 抑制因素
  • 機會

第5章 市場因素分析

  • 供應鏈分析
  • 波特的五力分析
  • API的製造工程
  • Duloxetine鹽酸鹽的合成
  • 法規方案
  • 美國的API的登記
  • EU的API的登記
  • 美國與EU的API登記必要條件比較
  • DuloxetineAPI的登記
  • 規格
  • 價格趨勢
  • 專利分析
  • Duloxetine鹽酸鹽的製劑相關專利分析
  • Duloxetine鹽酸鹽的控制釋放
  • 產品的開發平台分析

第6章 全球DuloxetineAPI市場:各用途

  • 概要
  • 重度憂鬱症
  • 廣泛性焦慮症(GAD)
  • 纖維肌痛
  • 神經性疼痛
  • 慢性肌肉骨骼痛
  • 其他

第7章 全球DuloxetineAPI市場:各地區

  • 簡介
  • 南北美洲
  • 歐洲
  • 亞太地區
  • 中東/非洲

第8章 競爭情形

第9章 企業簡介

  • Teva Pharmaceutical Industries Ltd
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma
  • Lupin
  • Zydus Cadila
  • Eli Lilly and Company
  • Shodhana Laboratories
  • Hetero
  • Apotex Inc.
  • Shionogi Inc.
  • Zhejiang Huahai Pharmaceutical Co., Ltd

第10章 附錄

目錄

Duloxetine API Market Information: by Application (Major Depressive Disorder, Generalized Anxiety Disorder (GAD), Fibromyalgia, Neuropathic Pain, Chronic Musculoskeletal Pain), by Region (Americas, Europe, Asia-Pacific, Others)-Forecast till 2023

Market analysis

Active pharmaceutical ingredients (APIs) are utilized in the assembling of pharmaceutical definitions. Duloxetine is a serotonin-norepinephrine reuptake inhibitor utilized in the treatment of discouragement and uneasiness. In addition, it is utilized to help mitigate neuropathic torment in individuals with diabetes or progressing torment because of ailments, for example, joint inflammation, unending back pain, or fibromyalgia. The developing predominance of misery, expanding entrance of conventional medications, expanding instances of nervousness, the developing pattern of outsourcing, strong drug pipeline, and developing interest for recently grown little particle medications are foreseen to support the market development over the forecast time frame. Be that as it may, the components, for example, changing monetary conditions in various areas and symptoms of duloxetine may frustrate the market development over the gauge time frame. The global duloxetine API market is anticipated to register a growth rate of CAGR 3.52% and is expected to reach the value of USD 3,985.0 million by the year 2023.

Market segmentation

The global duloxetine API market has been segmented on the basis of its application and regional demand. Based on its application, the market has been categorized into a generalized anxiety disorder, major depressive disorder, fibromyalgia, chronic musculoskeletal pain, neuropathic pain, and others.

Regional demand

Geographically, the global duloxetine API market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Shodhana Laboratories (India), Hetero (India), Apotex Inc. (Canada), Shionogi Inc. (US), and Zhejiang Huahai Pharmaceutical Co., Ltd (China), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Aurobindo Pharma (India), Lupin (India), Zydus Cadila (India), Eli Lilly and Company (United States), among others are some of the major players in the global duloxetine API market.

Table of Contents

1 Executive Summary

2 Market Introduction

  • 2.1 Definition
  • 2.2 Scope of the Study
  • 2.3 Market Structure

3 Research Methodology

  • 3.1 Research Process
  • 3.2 Primary Research
  • 3.3 Secondary Research
  • 3.4 Market Size Estimation
  • 3.5 Forecast Model

4 Market Dynamics

  • 4.1 Overview
  • 4.2 Drivers
    • 4.2.1 Rising Rates of Anxiety Cases
    • 4.2.2 Increasing Prevalence Rates of Depression
    • 4.2.3 Increasing Penetration of Generic Versions of Drugs
    • 4.2.4 Strong Drug Pipeline
    • 4.2.5 Growing Demand for Newly Developed Small Molecule Drugs
    • 4.2.6 Growing Trend of Outsourcing
  • 4.3 Restraints
    • 4.3.1 Changing Economic Conditions in Different Regions
    • 4.3.2 Side-Effects of Duloxetine
  • 4.4 Opportunities
    • 4.4.1 Advancements in API Manufacturing
    • 4.4.2 Patent Expiry Creating Opportunities for Generic and API Manufacturers

5 Market Factor Analysis

  • 5.1 Supply Chain Analysis
    • 5.1.1 Overview
    • 5.1.2 R&D
    • 5.1.3 Procurement of Raw Material
    • 5.1.4 Manufacturing
    • 5.1.5 Distributor
    • 5.1.6 End User
  • 5.2 Porter's Five Forces Model
    • 5.2.1 Overview
    • 5.2.2 Threat of New Entrants
    • 5.2.3 Bargaining Power of Suppliers
    • 5.2.4 Threat of Substitutes
    • 5.2.5 Bargaining Power of Buyers
    • 5.2.6 Intensity of Rivalry
  • 5.3 Manufacturing Process for API
  • 5.4 Synthesis of Duloxetine Hydrochloride
    • 5.4.1 General Process for Synthesis of Duloxetine Hydrochloride
    • 5.4.2 Variation in the Process According to Different Patents
  • 5.5 Regulatory Scenario
    • 5.5.1 Overview
  • 5.6 Registration of API in the US
    • 5.6.1 US Drug Master File (DMF)
  • 5.7 Registration of API in the European Union (EU)
    • 5.7.1 Active Substance Master File (ASMF)
  • 5.8 Comparison of requirements for the registration of API in the US and the EU
  • 5.9 Registration of Duloxetine API
  • 5.1 Specifications
  • 5.11 Pricing Evolution
  • 5.12 Patent Analysis
    • 5.12.1 Overview
    • 5.12.2 Patent Analysis for Duloxetine Drug
  • 5.13 Patent Analysis for the Preparation of Duloxetine Hydrochloride
    • 5.13.1 Methods for the Preparation of Duloxetine Hydrochloride
    • 5.13.2 Process for the Preparation of Duloxetine Hydrochloride
    • 5.13.3 Method for the Preparation of (S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine

Hydrochloride (duloxetine) 35

    • 5.13.4 Process for the Preparation of Duloxetine Hydrochloride
    • 5.13.5 Synthesis and Preparations of Duloxetine Salts
    • 5.13.6 Preparation of Chemically and Enantiomerically Pure Duloxetine HCl
    • 5.13.7 Antidepressant Oral Liquid Compositions
  • 5.14 Duloxetine Hydrochloride Delayed-Release Formulations
    • 5.14.1 Preparation of Duloxetine Hydrochloride Using Optically Active Methylhydroxylaminopropanol Compound as an Intermediate
    • 5.14.2 Process for the Preparation of Duloxetine Hydrochloride
    • 5.14.3 Process for Pure Duloxetine Hydrochloride
    • 5.14.4 Process for the Preparation of Pure Duloxetine Hydrochloride
    • 5.14.5 Process for the Preparation of Duloxetine Hydrochloride and its Precursors
  • 5.15 Product Pipeline Analysis
    • 5.15.1 Overview
    • 5.15.2 Duloxetine (Cymbalta) for Dysthymic Disorder and Depressive Disorder NOS
    • 5.15.3 Effect of Combined Morphine and Duloxetine on Chronic Pain
    • 5.15.4 Mechanistic Study of Duloxetine Versus Placebo in Breast Cancer Patients with Chronic Pain
    • 5.15.5 Duloxetine (LY248686) in the Treatment of Japanese Children and Adolescents with Depressive Disorder
    • 5.15.6 Perioperative Duloxetine for Pain Management After Laparoscopic Hysterectomy

6 Global Duloxetine API Market by Application

  • 6.1 Overview
  • 6.2 Major Depressive Disorder
  • 6.3 Generalized Anxiety Disorder (GAD)
  • 6.4 Fibromyalgia
  • 6.5 Neuropathic Pain
  • 6.6 Chronic Musculoskeletal Pain
  • 6.7 Others

7 Global Duloxetine API Market by Region

  • 7.1 Overview
  • 7.2 Americas
    • 7.2.1 North America
      • 7.2.1.1 US
      • 7.2.1.2 Canada
    • 7.2.2 Latin America
  • 7.3 Europe
    • 7.3.1 Western Europe
      • 7.3.1.1 Germany
      • 7.3.1.2 France
      • 7.3.1.3 UK
      • 7.3.1.4 Italy
      • 7.3.1.5 Spain
      • 7.3.1.6 Rest of Western Europe
    • 7.3.2 Eastern Europe
  • 7.4 Asia-Pacific
    • 7.4.1 China
    • 7.4.2 India
    • 7.4.3 Japan
    • 7.4.4 Rest of Asia-Pacific
  • 7.5 Middle East & Africa
    • 7.5.1 Middle East
    • 7.5.2 Africa

8 Competitive Landscape

  • 8.1 Introduction
  • 8.2 Company Ranking
  • 8.3 Key Customers

9 Company Profiles

  • 9.1 Teva Pharmaceutical Industries Ltd
    • 9.1.1 Company Overview
    • 9.1.2 Financial Overview
    • 9.1.3 Products/Services Offered
    • 9.1.4 Key Developments
    • 9.1.5 SWOT Analysis
    • 9.1.6 Key Strategies
  • 9.2 Sun Pharmaceutical Industries Ltd
    • 9.2.1 Company Overview
    • 9.2.2 Financial Overview
    • 9.2.3 Products/Services Offered
    • 9.2.4 Key Developments
    • 9.2.5 SWOT Analysis
    • 9.2.6 Key Strategies
  • 9.3 Aurobindo Pharma
    • 9.3.1 Company Overview
    • 9.3.2 Financial Overview
    • 9.3.3 Products/Services Offered
    • 9.3.4 Key Developments
    • 9.3.5 SWOT Analysis
    • 9.3.6 Key Strategies
  • 9.4 Lupin
    • 9.4.1 Company Overview
    • 9.4.2 Financial Overview
    • 9.4.3 Products/Services Offered
    • 9.4.4 Key Developments
    • 9.4.5 SWOT Analysis
    • 9.4.6 Key Strategies
  • 9.5 Zydus Cadila
    • 9.5.1 Company Overview
    • 9.5.2 Financial Overview
    • 9.5.3 Products/Services Offered
    • 9.5.4 Key Developments
    • 9.5.5 SWOT Analysis
    • 9.5.6 Key Strategies
  • 9.6 Eli Lilly and Company
    • 9.6.1 Company Overview
    • 9.6.2 Financial Overview
    • 9.6.3 Products Offering
    • 9.6.4 Key Developments
    • 9.6.5 SWOT Analysis
    • 9.6.6 Key Strategies
  • 9.7 Shodhana Laboratories
    • 9.7.1 Company Overview
    • 9.7.2 Financial Overview
    • 9.7.3 Products/Services Offered
    • 9.7.4 Key Developments
    • 9.7.5 SWOT Analysis
    • 9.7.6 Key Strategies
  • 9.8 Hetero
    • 9.8.1 Company Overview
    • 9.8.2 Financial Overview
    • 9.8.3 Products/Services Offered
    • 9.8.4 Key Developments
    • 9.8.5 SWOT Analysis
    • 9.8.6 Key Strategies
  • 9.9 Apotex Inc.
    • 9.9.1 Company Overview
    • 9.9.2 Financial Overview
    • 9.9.3 Products/Services Offered
    • 9.9.4 Key Developments
    • 9.9.5 SWOT Analysis
    • 9.9.6 Key Strategies
  • 9.1 Shionogi Inc.
    • 9.10.1 Company Overview
    • 9.10.2 Financial Overview
    • 9.10.3 Products/Services Offered
    • 9.10.4 Key Developments
    • 9.10.5 SWOT Analysis
    • 9.10.6 Key Strategies
  • 9.11 Zhejiang Huahai Pharmaceutical Co., Ltd
    • 9.11.1 Company Overview
    • 9.11.2 Financial Overview
    • 9.11.3 Products/Services Offered
    • 9.11.4 Key Developments
    • 9.11.5 SWOT Analysis
    • 9.11.6 Key Strategies

10 Appendix

  • 10.1 References
  • 10.2 Related Reports

List of Tables

  • TABLE 1 DIFFERENCES IN THE API REGISTRATION REQUIREMENTS IN THE US AND EU
  • TABLE 2 SPECIFICATIONS FOR DULOXETINE
  • TABLE 3 PRICE RANGE FOR DULOXETINE API (USD/KG)
  • TABLE 4 PATENT ANALYSIS FOR DULOXETINE DRUG
  • TABLE 5 DULOXETINE API MARKET: PRODUCT PIPELINE ANALYSIS
  • TABLE 6 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 7 GLOBAL DULOXETINE API MARKET FOR MAJOR DEPRESSIVE DISORDER, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 8 GLOBAL DULOXETINE API MARKET FOR GENERALIZED ANXIETY DISORDER (GAD), BY REGION, 2015-2023 (USD MILLION)
  • TABLE 9 GLOBAL DULOXETINE API MARKET FOR FIBROMYALGIA, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 10 GLOBAL DULOXETINE API MARKET FOR NEUROPATHIC PAIN, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 11 GLOBAL DULOXETINE API MARKET FOR CHRONIC MUSCULOSKELETAL PAIN, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 12 GLOBAL DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 13 GLOBAL DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)
  • TABLE 14 AMERICAS: DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 15 AMERICAS: DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)
  • TABLE 16 AMERICAS: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 17 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 18 NORTH AMERICA: DULOXETINE API MARKET VOLUME, BY COUNTRY, 2015-2023 (METRIC TON)
  • TABLE 19 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 20 US: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 21 CANADA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 22 LATIN AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 23 EUROPE: DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 24 EUROPE: DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)
  • TABLE 25 EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 26 WESTERN EUROPE: DULOXETINE API MARKET, BY COUNTRY, 2015-2023 (USD MILLION)
  • TABLE 27 WESTERN EUROPE: DULOXETINE API MARKET VOLUME, BY COUNTRY, 2015-2023 (METRIC TON)
  • TABLE 28 WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 29 GERMANY: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 30 FRANCE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 31 UK: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 32 ITALY: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 33 SPAIN: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 34 REST OF WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 35 EASTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 36 ASIA-PACIFIC: DULOXETINE API MARKET, BY COUNTRY, 2015-2023 (USD MILLION)
  • TABLE 37 ASIA-PACIFIC: DULOXETINE API MARKET VOLUME, BY COUNTRY, 2015-2023 (METRIC TON)
  • TABLE 38 ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 39 CHINA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 40 INDIA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 41 JAPAN: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 42 REST OF ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 43 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY REGION, 2015-2023 (USD MILLION)
  • TABLE 44 MIDDLE EAST & AFRICA: DULOXETINE API MARKET VOLUME, BY REGION, 2015-2023 (METRIC TON)
  • TABLE 45 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 46 MIDDLE EAST: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 47 AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2015-2023 (USD MILLION)
  • TABLE 48 GLOBAL DULOXETINE API MARKET, RANKING, 2017
  • TABLE 49 PROMINENT KEY CUSTOMERS FOR DULOXETINE (API)

List of Figures

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL DULOXETINE API MARKET: MARKET STRUCTURE
  • FIGURE 3 RESEARCH PROCESS OF MRFR
  • FIGURE 4 TOP-DOWN & BOTTOM-UP APPROACH
  • FIGURE 5 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL DULOXETINE API MARKET
  • FIGURE 6 SUPPLY CHAIN: GLOBAL DULOXETINE API MARKET
  • FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL DULOXETINE API MARKET
  • FIGURE 8 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2017 (%)
  • FIGURE 9 GLOBAL DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023 (USD MILLION)
  • FIGURE 10 GLOBAL DULOXETINE API MARKET, BY REGION, 2017 (%)
  • FIGURE 11 GLOBAL DULOXETINE API MARKET, BY REGION, 2017 AND 2023 (USD MILLION)
  • FIGURE 12 AMERICAS: DULOXETINE API MARKET, BY REGION, 2017 AND 2023
  • FIGURE 13 NORTH AMERICA: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023
  • FIGURE 14 EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023
  • FIGURE 15 WESTERN EUROPE: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023
  • FIGURE 16 ASIA-PACIFIC: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023
  • FIGURE 17 MIDDLE EAST & AFRICA: DULOXETINE API MARKET, BY APPLICATION, 2017 AND 2023